(Total Views: 737)
Posted On: 11/28/2021 4:31:48 PM
Post# of 145904
At $21 billion and 2x market cap Gilead got a bargain for Immunomedics and Trodelvy. If you take into account better drugs like leronlimab coming to the fore then it's merely a good price. Add longhaulers and NASH to the equation with their large patient populations and you can easily see where a $100+ billion market cap comes from and an even steeper buyout price. Then comes the myriad of other indications.
ps. From a financial standpoint the longer it takes for a combo HIV BLA to occur after an EUA the better.
ps. From a financial standpoint the longer it takes for a combo HIV BLA to occur after an EUA the better.
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)